Sequence search leader provides flagship solution to retrometabolic drug design company

Westborough, Massachusetts - June 5, 2007 – GenomeQuest, Inc., a leader in sequence search for research and IP, today announced that it is providing its flagship GenomeQuest™ solution to ARYx Therapeutics, a privately-held pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design.

GenomeQuest™ is a sequence search solution that enables biologists to evaluate novel gene sequences, and allows IP lawyers to evaluate freedom-to-operate, patentability, and competitive landscape features for the same sequences. The solution uniquely combines easy-to-use sequence search and analytics with public and proprietary sequence content, including the industry's largest and most complete indexed archive of close to 67 million patented sequences.

Dr. Jeff Anderson, Senior Manager of Intellectual Property at ARYx Therapeutics, said, "Understanding the patent landscape around biological sequences can be a very complex and time consuming process. ARYx has adopted GenomeQuest™ to simplify this process as we ramp up our molecular biology laboratory, to provide first-class sequence data and analysis for our researchers, as well as assisting us in maintaining and growing our significant IP in retrometabolic drug design."

Dr. Michael J. McManus, Vice President and General Manager of GenomeQuest, Inc., said, "We are delighted that ARYx has elected to work with GenomeQuest™ as they create new drug candidates to improve on existing therapeutics. Keeping our clients abreast of new sequences and patent information is critical to enabling exploration and defense of the IP landscape in this pursuit, and GenomeQuest™ is second-to-none in providing this capability."

About ARYx Therapeutics

ARYx Therapeutics is a privately-held pharmaceutical research and development company focused on addressing safety concerns in well-established and commercially successful existing therapies through application of its proprietary ARYx RetroMetabolic Drug Design™. ARYx improves today's drugs, making proven therapies safer. ARYx currently has three products in clinical trials. For more information, please see the company's web site at www.aryx.com.

About GenomeQuest, Inc.

GenomeQuest, Inc. is a leader in biological sequence search, content and analysis. Backed by an automatically-updated database that includes over 137 million sequence records, the company's flagship product, GenomeQuest™, is a Web-based search and analysis application that provides scientists and IP professionals with one source for the most comprehensive, accurate and complete sequence information available. Leading life sciences companies and IP law firms rely on GenomeQuest to help drive key scientific research and business decisions.

GenomeQuest, Inc., is headquartered in Westborough, Massachusetts. For more information, call (508) 616-0100, or visit www.genomequest.com.